Abstract
The first influenza pandemic in over 40 years was caused by a novel influenza A strain, A(H1N1)pdm09. Fortunately, most of those infected suffered mild disease. However, a significant minority of young adults and children exhibited severe illness, sometimes resulting in respiratory failure and even death. In the UK, A(H1N1)pdm09 influenza also caused a large disease burden the post-pandemic winter of 2010/11, stretching some healthcare resources to the limit. Although some pre-existing conditions increased the risk of severe disease, pregnant women and those with no underlying health problems contributed substantially to the total number of hospitalisations. Why outcomes of infection vary so widely is unknown and optimal personalised treatment strategies are yet to be developed. In this review, we give an overview of A(H1N1)pdm09 influenza in adults and the evidence supporting pharmacological interventions, with a focus on the use of antiviral agents.
Keywords: Antiviral, H1N1, influenza, pandemic, treatment, respiratory failure, vaccination, Dyspnoea, chronic obstructive pulmonary disease
Current Respiratory Medicine Reviews
Title:Severe Influenza: Clinical Features and Treatment Options
Volume: 8 Issue: 3
Author(s): Jake Dunning and Peter Openshaw
Affiliation:
Keywords: Antiviral, H1N1, influenza, pandemic, treatment, respiratory failure, vaccination, Dyspnoea, chronic obstructive pulmonary disease
Abstract: The first influenza pandemic in over 40 years was caused by a novel influenza A strain, A(H1N1)pdm09. Fortunately, most of those infected suffered mild disease. However, a significant minority of young adults and children exhibited severe illness, sometimes resulting in respiratory failure and even death. In the UK, A(H1N1)pdm09 influenza also caused a large disease burden the post-pandemic winter of 2010/11, stretching some healthcare resources to the limit. Although some pre-existing conditions increased the risk of severe disease, pregnant women and those with no underlying health problems contributed substantially to the total number of hospitalisations. Why outcomes of infection vary so widely is unknown and optimal personalised treatment strategies are yet to be developed. In this review, we give an overview of A(H1N1)pdm09 influenza in adults and the evidence supporting pharmacological interventions, with a focus on the use of antiviral agents.
Export Options
About this article
Cite this article as:
Dunning Jake and Openshaw Peter, Severe Influenza: Clinical Features and Treatment Options, Current Respiratory Medicine Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339812800493223
DOI https://dx.doi.org/10.2174/157339812800493223 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Autoantibodies as Biomarkers for ANCA-Associated Vasculitides
Current Immunology Reviews (Discontinued) Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology HCV and Autoimmunity in Rheumatic Diseases
Current Rheumatology Reviews Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Impact of Patient Knowledge of Hypertension Complications on Adherence to Antihypertensive Therapy
Current Hypertension Reviews Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Prospective of Natural Gum Nanoparticulate Against Cardiovascular Disorders
Current Chemical Biology The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Olanzapine-Induced Reversible Pellagroid Skin Lesion
Current Drug Safety Modelling the Neurovascular Unit and the Blood-Brain Barrier with the Unique Function of Pericytes
Current Neurovascular Research Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Commentary: Perivascular Fat and Improved Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology